|
Market Closed -
Bombay S.E.
06:02:28 2026-10-12 EDT
|
5-day change | 1st Jan Change | ||
| 1,759.10 INR | +0.13% |
|
-1.29% | +2.29% |
| 10-08 | Viatris Agrees to Acquire Pacira BioSciences in $1.65 Billion Deal | MT |
| 10-07 | India's Sun Pharmaceuticals to consider raising $1.55 billion via debentures | RE |
| Market Cap | 4,223B 44.18B 39.55B 36.87B 33.44B 63.07B 63.46B 443B 173B 2,179B 166B 162B 7,013B | P/E 2027 * |
32.7x | P/E 2028 * | 27.5x |
|---|---|---|---|---|---|
| Enterprise Value | 3,953B 41.35B 37.02B 34.51B 31.3B 59.03B 59.4B 415B 162B 2,040B 155B 152B 6,564B | EV / Sales 2027 * |
6.07x | EV / Sales 2028 * | 5.33x |
| Free-Float |
44.39% | Yield 2027 * |
0.97% | Yield 2028 * | 1.13% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| SUNPHARMA | Delayed | |
Bombay S.E.
| 524715 | Delayed |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.13% | ||
| 1 week | -1.29% | ||
| Current month | -3.35% | ||
| 1 month | -4.50% | ||
| 3 months | -9.10% | ||
| 6 months | +6.31% | ||
| Current year | +2.29% |
| 1 week | 1,744.95 |  | 1,803.35 |
| 1 month | 1,744.95 | | 1,890.4 |
| Current year | 1,583.6 | | 2,047.55 |
| 1 year | 1,583.6 | | 2,047.55 |
| 3 years | 1,069 | | 2,047.55 |
| 5 years | 733.95 | | 2,047.55 |
| 10 years | 315.2 | | 2,047.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 2025-08-31 | |
| Director of Finance/CFO | 58 | 2025-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 2025-08-31 | |
| Director/Board Member | 73 | 2018-05-24 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.13% | -1.29% | - | - | 43.63B | |
| +0.28% | +3.46% | +41.89% | +93.71% | 1,051B | |
| +0.88% | +4.27% | +38.28% | +68.70% | 630B | |
| +1.68% | +5.78% | +21.96% | +89.56% | 489B | |
| -0.10% | +4.24% | +69.15% | +40.41% | 359B | |
| +0.61% | +3.18% | +24.05% | +42.46% | 344B | |
| +0.72% | +2.99% | +14.29% | +34.71% | 272B | |
| +0.23% | +2.23% | -5.91% | +8.15% | 246B | |
| +0.65% | +3.62% | +43.93% | +46.50% | 224B | |
| -0.49% | +4.01% | +28.38% | +95.97% | 187B | |
| Average | +0.40% | +3.11% | +30.67% | +57.80% | 422.63B | |
| Weighted average by Cap. | +0.41% | +3.18% | +34.07% | +66.93% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.81B 6.1B 5.68B 5.16B 9.72B 9.79B 68.31B 26.74B 336B 25.59B 25.02B 1,081B | 729B 7.63B 6.83B 6.37B 5.78B 10.89B 10.96B 76.52B 29.96B 376B 28.66B 28.03B 1,211B |
| Net income | 129B 1.35B 1.21B 1.13B 1.02B 1.93B 1.94B 13.53B 5.3B 66.57B 5.07B 4.96B 214B | 154B 1.61B 1.44B 1.35B 1.22B 2.3B 2.32B 16.17B 6.33B 79.52B 6.06B 5.92B 256B |
| Net Debt | -270B -2.83B -2.53B -2.36B -2.14B -4.03B -4.06B -28.33B -11.09B -139B -10.61B -10.38B -448B | -338B -3.54B -3.17B -2.95B -2.68B -5.05B -5.08B -35.46B -13.88B -174B -13.28B -12.99B -561B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-12 | ₹1,759.10 | +0.13% | 55,944 |
| 26-10-09 | ₹1,756.90 | +0.25% | 73,516 |
| 26-10-08 | ₹1,752.50 | -1.72% | 229,287 |
| 26-10-07 | ₹1,783.25 | -0.99% | 57,412 |
| 26-10-06 | ₹1,801.00 | +1.07% | 23,216 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
- 524715 Stock
Select your edition
All financial news and data tailored to specific country editions
